

Friday August 25, 2023



2023 Interim Results Earnings Call

Dear Investors:

Hua Medicine (2552.HK) cordially invites you or your representative to attend the conference call for the Company's 2023 interim results, which will be held 9:00 AM HKT, August 25, 2023 (Friday).

During the conference call, management will provide a review of the Company's interim financial results in 2023, business updates, as well as address plans for the future.

Details of the earnings call are as follows:

Date:	August 25,2023
Time:	Login starts: 8:45AM HKT Meeting starts: 9:00AM HKT
Duration:	Approximately 50mins (including Q&A session)
Language:	English
Management:	Dr. Li Chen, Founder and CEO Mr. George Lin, EVP & Chief Strategy Officer
Moderator:	Christopher Lui, China Healthcare Analyst, Jefferies
RSVP:	Join zoom webinar: Hua Medicine Earnings Call *Please input your personal particulars and you will be directed to the page with connection details of this webinar.

About Hua Medicine

Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. As Hua Medicine's cornerstone product (dorzagliatin tablets), targeting the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients, it has been approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. Hua Medicine will partner with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing (华堂宁®) in China, benefiting diabetic patients and their families. HuaTangNing (华堂宁®) has also demonstrated its potential of achieving diabetes remission in clinical studies to help millions of diabetic patients around the world.